Jonathan E. Rosenberg, MD
Articles by Jonathan E. Rosenberg, MD

Jonathan E. Rosenberg, MD, explains the study design and patient inclusion criteria of the phase 2 EV-103 study investigating combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma.

Jonathan E. Rosenberg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, in reviewing the results of the EV-103 study in patients with metastatic or locally advanced urothelial carcinoma.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key data discussed during their conversation with Jonathan E. Rosenberg, MD, on the phase 2 EV-103 trial in metastatic or locally advanced urothelial carcinoma.

Experts explain how they would choose between combination therapy regimens for patients with metastatic or locally advanced urothelial carcinoma if the choice of treatment was not influenced by low supply availability.

Key opinion leaders discuss the available data on combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma and an FGFR mutation.

Jonathan E. Rosenberg, MD, discusses what has been previously shown with enfortumab vedotin for patients with locally advanced metastatic urothelial cancer.

Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses what is on the horizon for the treatment landscape of bladder cancer.